Curr Opin Infect Dis. 1998 Dec;11(6):691-705. doi: 10.1097/00001432-199812000-00008.
Current opinion in infectious diseases
R G Ridley, A T Hudson
PMID: 17035745 DOI: 10.1097/00001432-199812000-00008
Clinical trials continue to provide evidence for the efficacy of semi-synthetic artemisinin derivatives and the novel fixed dose combination therapies Malarone, co-artemether and chlorproguanil-dapsone. Single agents under development include the 8-aminoquinoline etaquine, pyronaridine and azithromycin. Preclinical interest in synthetic endoperoxides and quinoline analogues remains high and a significant is also being made in natural product chemistry. Dihydrofolate reductase remains a molecular drug target of interest, whereas phospholipid metabolism represents a new approach. Genomic information is likely to produce many new drug targets for exploration in the coming decade.
